Adipose tissue-derived mesenchymal stem cells (AT-MSCs) are currently used for bone tissue engineering. AT-MSCs undergoing osteogenic differentiation, as well as mature bone cells, respond to mechanical loading with increased cyclooxygenase-2 gene expression, a key enzyme in prostaglandin synthesis. Prostaglandins (PGs) are potent multifunctional regulators in bone, exhibiting stimulatory and inhibitory effects on bone formation and resorption. PGE 2 , but not PGI 2 or PGF 2α , recruits osteoprogenitors from the bone marrow space and influences their differentiation. We hypothesize that PGE 2 , PGI 2 , and PGF 2α may differentially regulate osteogenic differentiation of human AT-MSCs.
INTRODUCTION
Adipose tissue-derived mesenchymal stem cells (AT-MSCs) serve as a more efficient source of autologous adult mesenchymal stem cells than bone marrow-derived mesenchymal stem cells due to greater availability, and could thus have significant potential for therapeutic use. 1, 2 Mesenchymal stem cells from adipose tissue and bone marrow are currently under evaluation for bone tissue engineering applications. [3] [4] [5] [6] After appropriate stimulation AT-MSCs can differentiate towards multiple lineages, such as the adipogenic, chondrogenic, myogenic, and osteogenic lineage. 5, 7, 8 In addition, 1,25-dihydroxyvitamin D 3 -treated AT-MSCs respond to mechanical loading by fluid shear stress in a bone cell-like manner with enhanced nitric oxide production and increased cyclooxygenase-2 (COX-2) gene expression, thereby indicating that AT-MSCs might be able to perform bone cell-specific functions during bone (re)modelling. 4 Prostaglandins are abundantly produced by osteocytes and other cells of the osteoblastic lineage in response to factors such as mechanical stimulation and play an important role during bone remodelling. [9] [10] [11] [12] Prostaglandins have both inhibitory and stimulatory effects on bone cells and organ cultures, and the most abundant prostaglandin in bone, prostaglandin E 2 (PGE 2 ) has been shown to have a biphasic effect on osteoclastogenesis and osteoblast function. 9,10,13,14 PGE 2 at relatively low concentrations or in the presence of glucocorticoids stimulates the replication and differentiation of osteoblasts and increases bone formation. 10, 13, 15 However, PGE 2 at high concentrations or in the presence of insulin-like growth factor-I inhibits collagen synthesis. 10, 13, 16 Mature bone cells produce PGE 2 , PGI 2 (also referred to as prostacyclin), and PGF 2α upon stimulation by e.g. fluid shear stress. PGE 2 has been shown to recruit osteoprogenitor cells from the bone marrow space and influence their differentiation into osteoblasts. [17] [18] [19] However, the effect of PGF 2α and PGI 2 on recruitment of osteoprogenitor cells from the bone marrow and their differentiation into osteoblasts is unknown. Hence, the aim of this study was to compare the effects of exogenous PGE 2 , PGI 2 , and PGF 2α on proliferation and osteogenic differentiation of AT-MSCs in vitro. We hypothesized that differentiation of AT-MSCs towards the osteogenic lineage can be differentially regulated by prostaglandins, which are locally produced in bone.
Osteogenic differentiation of AT-MSCs was assessed by measuring ALP activity and gene expression of runx-2, OPN, and COL1A1.
MATERIALS AND METHODS

Donors
Human subcutaneous adipose tissue samples were obtained as waste material after elective surgery and donated upon informed consent of the patients by the departments of plastic surgery from clinics in The Netherlands. Adipose tissue was taken from three patients, two female patients and one male (age; 28, 42, and 49 years). The ethical review board of the Vrije Universiteit approved the protocol.
AT-MSC isolation and storage
Adipose tissue was harvested by tumescent liposuction from three donors, whereby a hollow blunt-tipped cannula was introduced into the subcutaneous space through a small incision, and a 0.65% NaCl solution (Baxter, Utrecht, The Netherlands) supplemented with vasoconstriction agents was infused into the adipose compartment to minimize blood loss and tissue contamination with peripheral blood cells prior to aspiration. Adipose tissue was aspirated by gentle suction after the adipose compartment was mechanically disrupted by moving the cannula. 35 ATMSCs were isolated from the lipoaspirate as described earlier with minor modifications. 2, 4, 5, 7, 35 In short, the lipoaspirate was enzymatically digested for 45 min 
AT-MSC culture
Cryopreserved, AT-MSCs containing cell suspensions were thawed and seeded at 4-10 x 10 4 cells/cm 2 in culture medium which was composed of D-MEM containing 10%
FBS (Gibco, Paisley, UK) supplemented with 500 µg/ml streptomycin sulphate (Sigma-Aldrich, St. Louis, MO, USA), 600 µg/ml penicillin (Sigma-Aldrich), and 2.5 µg/ml amphotericin B (Fungizone, Gibco). AT-MSCs were incubated at 37°C under 5% CO 2 , and medium was exchanged every three to four days. The culture period right after isolation is defined as passage 0. Upon confluence, AT-MSCs were harvested using 0.25% trypsin and 0.1% EDTA in PBS, seeded in 75 cm 2 culture flasks (Greiner Bio-One, Kremsmuenster, Austria), and cultured until the cell layer reached confluence again (passage 1). AT-MSCs used in this study where used at passage four or passage five.
AT-MSC characterization
Human AT-MSCs at passage 1 were analyzed for the expression of the mesenchymal stem cells surface markers CD105/endoglin and CD166/ALCAM by fluorescence-activated cell sorting (FACS) as described earlier. 
Alkaline phosphatase and protein
To assess the osteoblastic phenotype of AT-MSCs after 4 days of treatment with PGE 2 , PGI 2 , and PGF 2α , ALP activity was measured. Cells were seeded at 3.6 x 10 4 cells per well in 24-well culture dishes (Greiner Bio-One, Kremsmuenster, Austria), cultured for 4 days as described above, and alkaline phosphatase (ALP) activity and protein content were determined in the cell lysate. P-nitrophenyl phosphate (Merck) at pH 10.3 was used as substrate to determine ALP activity, according to the method described by Lowry. 38 The absorbance was read at 410 nm with a micro plate reader (BioRad Laboratories Inc.).
The amount of protein was determined using a BCA Protein Assay Reagent kit (Pierce, Rockford, IL, USA), and the absorbance was read at 570 nm with a micro plate reader (BioRad Laboratories Inc.).
Analysis of gene expression
Total RNA was isolated according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA). cDNA synthesis was performed using 0. Runx-2, runt-related factor-2; OPN, osteopontin; COL1A1, α1(I)procollagen
Statistical analysis
Data were obtained from 3 separate donors. For statistical analysis treatment-overcontrol-ratios (T/C-ratios) ALP activity and runx-2 gene expression data were calculated and data are shown as mean ± SEM. Changes in total amount of DNA over time was evaluated using a One-Way ANOVA. Differences of T/C-ratios were tested with a one-tailed t-test for single group mean and compared to 1 (T/C = 1, no effect). Gene expression data OPN, COL1A1 are shown as mean ± SEM and differences between groups where tested with a one-tailed unpaired t-test.
Differences were considered significant if p<0.05.
RESULTS
To evaluate the effects of PGE 2 , PGI 2 , and PGF 2α at 0.01-10 µM on AT-MSC proliferation, the increase in the total amount of DNA from day 1 to day 4 was determined (Fig 1) . PGE 2 , PGI 2 , and PGF 2α at 0.01-10 µM did not affect proliferation of AT-MSCs compared to controls (Fig 1) . Nevertheless, the total amount of DNA per well was significantly increased over time in controls and after treatment with PGE 2 , PGI 2 and PGF 2α at all concentrations tested (Fig 1) . The total amount of protein at day 4 in untreated controls was 87.4±7.0 µg/well (mean ± SEM) and was not changed by PGE 2 , PGI 2 , or PGF 2α at 0.01-10 µM (data not shown). In order to study the effect of PGE 2 , PGI 2 , and PGF 2α on osteogenic differentiation, ALP activity and gene expression of runx-2, OPN, and COL1A1 in ATMSCs were determined at day 4. PGF 2α at 0.01-10 µM increased ALP activity by 1.3-1.5-fold, whereas PGE 2 and PGI 2 at 0.01-10 µM did not affect ALP activity in ATMSCs (Fig 2) . Values are means ± SEM of prostaglandin-treated-over-control ratios (T/C, n = 3), dashed line, T/C = 1 (no effect). PGE 2 , prostaglandin E 2 ; PGI 2 , prostaglandin I 2 ; PGF 2α , prostaglandin F 2α ; AT-MSCs, adipose tissue-derived mesenchymal stem cells; ALP, alkaline phosphatase. * Significant effect of prostaglandins, p<0.05. Values are means ± SEM of prostaglandin-treated-over-control ratios (T/C, n = 3), dashed line, T/C = 1 (no effect). Real-time PCR data were normalized for 18S gene expression. PGE 2 , prostaglandin E 2 ; PGI 2 , prostaglandin I 2 ; PGF 2α ,     prostaglandin F 2α ; AT-MSCs, adipose tissue-derived mesenchymal stem cells; runx-2, runt-related factor-2. Significant effect of prostaglandins, * p<0.05; ** p<0.01.
PGF 2α at 0.01 and 0.1 µM upregulated OPN gene expression in AT-MSCs by 2.4-fold (0.01 µM) and 2-fold (0.1 µM), but PGF 2α at 1 and 10 µM had no effect ( Fig   4A) . PGE 2 at all concentrations tested did not affect OPN gene expression in ATMSCs (Fig 4A) . PGI 2 at 0.01 µM upregulated OPN gene expression by 1.9-fold, while PGI 2 at 0.1-10 µM had no effect (Fig 4A) . PGF 2α at 0.01 and 0.1 µM upregulated COL1A1 gene expression in AT-MSCs by 1.3-fold (0.01 µM) and 1.2-fold (0.1 µM),
while PGF 2α at 1 and 10 µM had no effect (Fig 4B) . PGE 2 and PGI 2 at all concentrations tested (0.01-10 µM) did not affect COL1A1 gene expression in ATMSCs (Fig 4B) .
PGE 2 and PGF 2α at 10 µM downregulated runx-2 gene expression by 1.9-fold and 1.4-fold, respectively, whereas PGI 2 at 10 µM had no effect (Fig 3) . PGE 2 , PGI 2 and PGF 2α at 0.01-1 µM did not affect runx-2 gene expression (Fig 3) . 
DISCUSSION
Prostaglandins are potent multifunctional regulators of bone metabolism. 39 The present study compares the effects of three naturally occurring prostaglandins in bone, i.e. PGE 2 , PGI 2 , and PGF 2α , on proliferation and osteogenic differentiation of AT-MSCs. PGE 2 , PGI 2 , and PGF 2α did not affect proliferation of AT-MSCs compared to control cultures. PGF 2α stimulated ALP activity and gene expression of the bone extracellular matrix proteins OPN and COL1A1. PGI 2 increased OPN gene expression, but PGE 2 had no effect. The increase in ALP activity and gene expression of OPN and COL1A1 suggests that AT-MSCs undergo osteogenic differentiation after treatment with PGF 2α , but not after treatment with PGE 2 or PGI 2 .
Our finding suggests that PGF 2α is a more potent stimulator of osteogenic differentiation of AT-MSCs than PGE 2 and PGI 2 . Prostaglandins seem to have different effects dependening on the differentiation stage of the cells, since an earlier study in rat osteoblastic clonal Py1a cells showed that PGF 2α  was more effective than PGE 2 and PGI 2 in inhibiting COL1A1 synthesis and gene expression in the presence of insulin-like growth factor 1. 34 Moreover, in mouse bone organ cultures PGF 2α was less potent in increasing bone formation than PGE 2 , but it stimulated endogenous PGE 2 production. 40 PGE 2 has been suggested to recruit osteogenic progenitors from the bone marrow space thereby stimulating their osteogenic differentiation, as was shown by increased nodule formation and increased ALP activity by rat bone marrow-derived stromal cells. 41 We found that ALP activity in human AT-MSCs was increased by PGF 2α , but not by PGE 2 . Both PGE 2 and PGF 2α stimulated cell proliferation and collagen production in osteoprogenitor cells obtained from fetal rat bone, while mature bone cells from these bones were less stimulated. 42 Systemic administration of PGE 2 enhances the osteogenic capacity of bone marrow derived mesenchymal stem cells in rats. 50 Local and systemic administration of EP4 receptor-selective agonists enhancing ectopic bone formation induced by recombinant human BMP-2 in mice, suggests a direct coupling of these two pathways. 51, 52 We have shown earlier that AT-MSCs differentiate towards the osteogenic lineage after BMP-2 treatment. 5 The cross-talk between BMP-2 and prostaglandins, and the increase in bone formation after systemic administration of prostaglandins might have implications for the therapeutical use of AT-MSCs.
Possibly, AT-MSCs triggered with BMP-2 in combination with the systemic or local application of prostaglandins might support or enhance bone formation at the grafting site in patients during bone tissue engineering applications. 5, 53 However, it remains to be elucidated whether treatment of AT-MSCs with BMP-2 in combination with prostaglandins (PGF 2α ) has a beneficial effect on their osteogenic differentiation.
Prostaglandins are involved in their own endogenous regulation and PGF 2α
can increase endogenous PGE 2 production. 40, 54 Our study shows that exogenous PGF 2α increases OPN and COL1A1 gene expression, and ALP activity, whereas exogenous PGE 2 did not. This suggests that the observed effects of PGF 2α were not caused by a stimulation of endogenous PGE 2 production. This issue can be addressed by decreasing endogenous prostaglandin production, e.g. by using cortisol. 13, 55 We have chosen not to add cortisol to our experimental cultures, since cortisol has been shown to promote adipogenic differentiation of murine ST-2 stromal cells. 56 In conclusion, prostaglandins, which are potent local lipid mediators produced in bone, influence osteogenic differentiation of AT-MSCs. We have shown that exogenous PGF 2α stimulates osteogenic differentiation of human AT-MSCs in vitro and that it is more potent than PGE 2 and PGI 2 . Thus, once AT-MSCs are placed in a natural bone environment, i.e. during bone tissue engineering applications, locally produced prostaglandins (PGF 2α ) might be beneficial in promoting osteogenic differentiation of AT-MSCs in vivo.
